MarketCap
Vertex Pharmaceuticals Incorporated VRTX
Facebook
X
Telegram
Country |
 USA |
IPO year |
1991 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
256 M |
Market Cap[1] |
$ 128 B |
EBITDA (LTM) |
$ 4.38 B |
P/E (LTM) |
35.324709 |
P/S (LTM) |
11.635646 |
EPS (LTM) |
15.46 |
Vertex Pharmaceuticals is an American biotechnology company specializing in the development of drugs for the treatment of rare diseases. The company was founded in 1989 in Cambridge, Massachusetts.
Vertex Pharmaceuticals' main area of focus is the research and development of new drugs for the treatment of genetic diseases such as cystic fibrosis, Berger's syndrome, thalassemia, and others.
One of the company's most well-known products is the drug Kalydeco, which is used to treat cystic fibrosis. In addition, Vertex Pharmaceuticals is working on the development of new drugs for the treatment of cancer, Parkinson's disease, and other conditions.
The company actively invests in scientific research and the development of new drugs. Vertex Pharmaceuticals collaborates with universities, research centers, and other companies to expand its scientific potential and improve its products.
Vertex Pharmaceuticals has a wide network of distributors and partners around the world, which allows it to provide its products to patients in various countries. The company strives for continuous improvement of its products and expansion of its activities to meet the needs of patients worldwide.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
- | - | $ 112 M | Nasdaq Global Select Market |  Canada |
 |
Sesen Bio
SESN
|
- | 7.29 % | $ 127 M | Nasdaq Global Select Market | USA |
 |
Windtree Therapeutics
WINT
|
- | - | $ 26.8 M | Nasdaq Global Select Market | USA |
 |
Trean Insurance Group
TIG
|
- | - | $ 316 M | Nasdaq Global Select Market | USA |
 |
SQZ Biotechnologies Company
SQZ
|
- | 57.95 % | $ 12.8 M | NYSE | USA |
 |
MEI Pharma
MEIP
|
- | 10.43 % | $ 20.5 M | Nasdaq Capital Market | USA |
 |
Palatin Technologies
PTN
|
- | - | $ 13 M | NYSE American | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
ММЦБ
GEMA
|
- | - | - | MOEX | Russia |
 |
Lyra Therapeutics
LYRA
|
- | - | $ 24.9 M | Nasdaq Global Market | USA |
 |
Завод ДИОД
DIOD
|
- | - | - | MOEX,SPB | Russia |
 |
Фармсинтез
LIFE
|
- | - | - | MOEX | Russia |
 |
ОЗОН Фармацевтика
OZPH
|
- | - | - | MOEX | Russia |
 |
Промомед
PRMD
|
- | - | - | MOEX | Russia |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
ESSA Pharma
EPIX
|
- | - | $ 8.86 M | Nasdaq Capital Market | Canada |
 |
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | USA |
 |
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | Nasdaq Global Market | USA |
 |
Merus N.V.
MRUS
|
- | - | $ 5.78 B | Nasdaq Global Select Market |  Niderland |
 |
RAPT Therapeutics
RAPT
|
- | - | $ 2.36 B | Nasdaq Global Select Market | USA |
 |
Exicure
XCUR
|
$ 1.12 | 0.88 % | $ 7.05 M | Nasdaq Capital Market | USA |
 |
Cellectis S.A.
CLLS
|
$ 1.04 | 1.36 % | $ 104 M | Nasdaq Global Market |  France |
 |
AbCellera Biologics
ABCL
|
$ 11.8 | 2.51 % | $ 3.52 B | Nasdaq Global Select Market | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 55.9 | 0.22 % | $ 7.48 B | Nasdaq Global Select Market,SPB | USA |
 |
BioMarin Pharmaceutical
BMRN
|
$ 54.68 | 1.65 % | $ 10.5 B | Nasdaq Global Select Market,SPB | USA |
 |
Celldex Therapeutics
CLDX
|
$ 27.53 | 3.93 % | $ 1.83 B | Nasdaq Global Select Market | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
$ 3.63 | 0.64 % | $ 44.3 M | Nasdaq Capital Market |  Israel |
 |
Jaguar Health
JAGX
|
$ 3.53 | 9.81 % | $ 8.23 M | Nasdaq Capital Market | USA |
 |
Protalix BioTherapeutics
PLX
|
$ 2.62 | 3.05 % | $ 206 M | NYSE American | Israel |
 |
uniQure N.V.
QURE
|
$ 21.78 | 7.39 % | $ 1.25 B | Nasdaq Global Select Market | Niderland |
 |
Stoke Therapeutics
STOK
|
$ 24.17 | 5.8 % | $ 1.43 B | Nasdaq Global Select Market,SPB | USA |
 |
Xencor
XNCR
|
$ 22.85 | 2.61 % | $ 1.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Annexon
ANNX
|
$ 3.41 | 1.09 % | $ 529 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.76 | 0.54 % | $ 2.9 M | NYSE American | Israel |
 |
Incyte Corporation
INCY
|
$ 113.07 | 0.03 % | $ 22.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Mesoblast Limited
MESO
|
$ 13.28 | 1.16 % | $ 16 B | Nasdaq Global Select Market |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
$ 9.28 | 5.1 % | $ 746 M | Nasdaq Global Select Market | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 225.25 | 0.42 % | $ 13.7 B | Nasdaq Global Select Market |  Danmark |
 |
Axon Enterprise
AXON
|
$ 390.29 | 2.15 % | $ 30.5 B | Nasdaq Global Select Market,SPB | USA |
 |
AbbVie
ABBV
|
$ 285.42 | 0.71 % | $ 505 B | NYSE,SPB | USA |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.72 | 2.35 % | $ 97.8 M | Nasdaq Global Select Market,SPB | USA |
 |
Altimmune
ALT
|
$ 2.2 | 2.16 % | $ 194 M | Nasdaq Global Market | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.22 | 2.39 % | $ 809 M | Nasdaq Global Select Market | Canada |
 |
Oncternal Therapeutics
ONCT
|
- | -24.12 % | $ 1.56 M | Nasdaq Capital Market | USA |
 |
Catalyst Biosciences
CBIO
|
$ 11.84 | 0.87 % | $ 1.06 B | Nasdaq Capital Market | USA |
 |
Seagen
SGEN
|
- | - | $ 42.2 B | Nasdaq Global Select Market,SPB | USA |
 |
Codexis
CDXS
|
$ 1.24 | 5.43 % | $ 108 M | Nasdaq Global Select Market | USA |
 |
Cullinan Management
CGEM
|
$ 12.93 | 2.64 % | $ 779 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.